gradientForSurfBreak.png

Item List

PR Newswire
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing

Invitae ( NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae's Ciitizen platform were utilized as natural history data to support the submission of Praxis' Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developmental and epileptic encephalopathy (DEE). Praxis announced earlier this month that the U.S. Food and Drug Administration (FDA) cleared the IND application for the initial dose cohort for the PRAX-222 EMBRAVE clinical study.

Recent Posts

General News

Carlsmed.png

At HLTH 2022, a New Chapter for AI
...

MedCity News

General News

Carlsmed.png

HCA CEO to Big Tech: You Can’t Disrupt Healthcare Like You’ve Disrupted Other In ...

MedCity News

Wavemaker 360 News

Carlsmed.png

Wavemaker Three-Sixty Health Celebrates Investment Milestone at HLTH 2022: 50 Co ...

Yahoo

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png